NEW YORK, March 21, 2017 -- Pomerantz LLP announces that a class action lawsuit has been filed against Omega Protein Corporation (“Omega” or the “Company”) (NYSE:OME) and certain of its officers. The class action, filed in United States District Court, Central District of California, is on behalf of a class consisting of investors who purchased or otherwise acquired Omega securities, seeking to recover compensable damages caused by defendants’ violations of the Securities Exchange Act of 1934.
If you are a shareholder who purchased Omega securities between August 3, 2016 and March 1, 2017, both dates inclusive, you have until May 1, 2017 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll free, ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased.
[Click here to join this class action]
Omega develops, produces, and delivers products to enhance the nutritional integrity of foods, dietary supplements, and animal feeds worldwide.
The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the SEC is requesting information in connection with an investigation relating to Omega’s subsidiary’s compliance with its probation terms and Omega’s protection of whistleblower employees; (2) it is possible that the foregoing matter could result in a material adverse effect on Omega’s business, reputation, results of operation and financial condition; and (3) as a result, Defendants’ statements about Omega’s business, operations and prospects were materially false and misleading and/or lacked a reasonable bases at all relevant times.
On March 1, 2017, during aftermarket hours, Omega filed a Form 10-K for the fiscal year ended December 31, 2016 with the SEC, revealing that in December 2016, it “received a subpoena from the SEC requesting information in connection with an investigation relating to a Company subsidiary’s compliance with its probation terms and the Company’s protection of whistleblower employees.” Omega further revealed that “it is possible that the foregoing matter could result in a material adverse effect on the Company’s business, reputation, results of operation and financial condition.”
On this news, shares of Omega fell $6.25 per share or over 23.81% from its previous closing price to close at $20.00 per share on March 2, 2017, damaging investors.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com
CONTACT: Robert S. Willoughby Pomerantz LLP [email protected]


SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 



